Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 6:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 2,369 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, etoposide, mesna, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Temple University
Other
Eligibility
15 Years to 60 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1991 – 2003
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Not applicable Interventional Accepts healthy volunteers

Nutrition Intervention to Promote Immune Recovery From Sleep Restriction

NCT03525184
Conditions
Sleep Restriction
Interventions
Additional protein and multi-nutrient beverage, Placebo beverage
Other
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Natick, Massachusetts
Conditions
Alzheimer's Disease
Interventions
placebo, donepezil, ABT-126
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
55 Years to 90 Years
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
8
States / cities
Delray Beach, Florida • Tampa, Florida • West Palm Beach, Florida + 5 more
Conditions
Leukemia
Interventions
Rituximab, Imatinib, Cyclophosphamide, Doxorubicin, Mesna, VSLI, Solu-Medrol, Methotrexate, Ara-C, G-CSF, Pegfilgrastim, Dexamethasone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Three New Ideas to Protect Special Forces From the Stress of High Altitude

NCT02463357
Conditions
Mountain Sickness
Interventions
Quercetin, Nifedipine extended release, Methazolamide, Metformin, Placebo, Nitrite
Dietary Supplement · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Alma, Michigan
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
Interventions
therapeutic allogeneic lymphocytes, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, Total Body Irradiation (TBI), Granulocyte colony-stimulating factor (G-CSF), Phenytoin, Methotrexate
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Neuroblastoma
Interventions
Filgrastim, Carboplatin, Etoposide, Melphalan, Peripheral blood stem cell infusion, 131I-MIBG, Radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
1 Year to 29 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more
Conditions
Hypoxic Ischemic Encephalopathy
Interventions
Darbepoetin alfa, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
Up to 24 Hours
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Albuquerque, New Mexico • Nashville, Tennessee • Ogden, Utah + 3 more
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, melphalan, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Temple University
Other
Eligibility
16 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Secondary Post Tonsillectomy Hemorrhage, Primary Post Tonsillectomy Hemorrhage
Interventions
Ibuprofen
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Fort Sam Houston, Texas • Lackland Air Force Base, Texas • Tacoma, Washington
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Completed Not applicable Interventional Accepts healthy volunteers

Thermic & Lipemic Properties of Dietary Carbohydrates

NCT01354574
Conditions
Exogenous Obesity, Dietary Modification
Interventions
High Glycemic Index meals, Low Glycemic Index meals
Other
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
18 Years to 48 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Davis, California
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Chordoma, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma
Interventions
amifostine trihydrate, busulfan, filgrastim, melphalan, thiotepa, peripheral blood stem cell transplantation (PBSC)
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
1 Year to 45 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Added Sugar Intake on Brain Blood Flow and Hippocampal Function in Midlife Adults

NCT05211726
Conditions
Aging, Healthy Diet
Interventions
Low Added Sugar Diet, High Added Sugar Diet
Other
Lead sponsor
University of Delaware
Other
Eligibility
50 Years to 64 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Newark, Delaware
Conditions
Bronchopulmonary Dysplasia of Newborn
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
Christoph Hornik
Other
Eligibility
Up to 29 Weeks
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
25
States / cities
Little Rock, Arkansas • San Diego, California • Washington D.C., District of Columbia + 19 more
Conditions
Sarcoma
Interventions
filgrastim, dacarbazine, doxorubicin hydrochloride, ifosfamide, mesna, conventional surgery, brachytherapy, intraoperative radiation therapy, radioisotope therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2013
U.S. locations
220
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 169 more
Conditions
ENSAT Stage I Adrenal Cortex Carcinoma, ENSAT Stage II Adrenal Cortex Carcinoma, ENSAT Stage III Adrenal Cortex Carcinoma
Interventions
Cisplatin, Etoposide, Mitotane, Quality-of-Life Assessment
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
3
States / cities
Ann Arbor, Michigan • St Louis, Missouri • Houston, Texas
Completed Phase 1Phase 2 Interventional Results available

Berinert (C1INH) vs Placebo for DGF/IRI

NCT04696146
Conditions
End Stage Renal Disease, Chronic Kidney Diseases
Interventions
Berinert, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Myelodysplastic Syndromes
Interventions
Vitamin C
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Miami, Florida • New York, New York
Conditions
Hypertension, Heart Failure
Interventions
Clevidipine, Standard of Care IV antihypertensive
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
9
States / cities
Montgomery, Alabama • Inglewood, California • Baton Rouge, Louisiana + 6 more
Conditions
Nausea, Vomiting
Interventions
Ginger, Placebo Oral Tablet
Drug
Lead sponsor
Joel Yarmush
Other
Eligibility
20 Years to 49 Years · Female only
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Brooklyn, New York
Conditions
Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, fludarabine, mycophenolate mofetil, stem cell transplantation, total body irradiation, filgrastim
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 80 Years
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
51
States / cities
Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 46 more
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Part A: RPL554, Part B: RPL554, Placebos
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
40 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Union, South Carolina